Sanofi-Synthelabo’s Eloxatin for Postsurgical Treatment of Stage III Colon Cancer
November 5, 2004 by admin · Leave a Comment
On November 5, 2004 Sanofi-Synthelabo’s Eloxatin™ (oxaliplatin for injection) received US FDA approval for use in combination with conventional chemotherapy (5-flurouracil and leukovorin) for the postsurgical treatment of stage III colon cancer patients. According to the company, this is the first new chemotherapy approval for the adjuvant treatment of colon cancer in over a decade. [...]
Acomplia (rimonabant)
March 12, 2004 by admin · Leave a Comment
On March 9, 2004 Sanofi-Synthelabo announced preliminary Phase III results for Acomplia™ (rimonabant), in two clinical trials: the Stratus-US (smoking cessation) trial and the RIO-Lipids/weight loss (obesity) trial. The Stratus-US trial randomized 787 smokers who wanted to quit to use either a placebo, a 5-milligram daily dose of Acomplia or a 20-milligram daily dose, in [...]